Clinical and Sonographic Differences Between RET Fusion-positive and BRAFV600E in Papillary Thyroid Carcinoma
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae803 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Zixian Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200001, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Cancer, Papillary, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-ret. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Purpose
This study aimed to describe the ultrasound characteristics of papillary thyroid carcinoma (PTC) harboring RET gene fusion and explore its clinical significance.
Methods
A retrospective study was conducted on 209 patients with PTC diagnosed between August 2021 and January 2024. All patients underwent ultrasound examination and were confirmed to be positive for RET fusion or BRAFV600E by pathological results. The differences in clinical characteristics and ultrasonography features between the 2 groups were analyzed.
Results
Among all PTCs (n = 209), we detected 30 RET fusions and 179 BRAFV600E. RET-fusion PTCs showed younger age [38.5 (16.0-69.0) vs 42.9 (20.0-74.0) years, P < .05], larger tumor size [1.09 (0.5-4.0) vs 0.77 (0.1-4.0) cm, P < .005], and more advanced N stage (P < .001) than BRAFV600E PTCs. RET-fusion PTCs were mainly classical and diffuse sclerosing subtypes. In terms of ultrasound performance, RET-fusion PTCs were mainly manifested as heterogeneous echogenicity (43.3%), ill-defined tumor margin (90.0%), irregular shape (83.3%), and intranodular microcalcification (83.3%), characterized by scattered microcalcification around the tumor/within thyroid gland (40.0%). In comparison, BRAFV600E PTCs were mainly characterized by hypoechogenicity (95.5%), round/oval shape (80.4%), and intranodular noncalcification (54.2%). Multivariate logistic regression analysis revealed that scattered microcalcification around the tumor/within the normal gland was an independent risk factor for lateral lymph node metastasis (LLNM) in RET-fusion PTCs (odds ratio 9.79, 95% confidence interval 1.31-72.93, P = .026).
Conclusion
Patients diagnosed with PTC harboring RET fusion presented with distinctive clinical characteristics and sonographic patterns, underscoring the unique diagnostic value of ultrasound examination. It can provide a preoperative noninvasive primary screening method for RET-fusion diagnosis, thus facilitating targeted patients with purposeful molecular sequencing to improve treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200001, China.
- Department of Ultrasonography, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200001, China.
ORCID-Profile: Zhuoying Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, Z., Sun, W., Fei, M., Qian, K., Shi, Y., Guo, K., & Wang, Z. (2025). Clinical and Sonographic Differences Between RET Fusion-positive and BRAFV600E in Papillary Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae803
Vancouver
Chen Z, Sun W, Fei M, Qian K, Shi Y, Guo K, et al. Clinical and Sonographic Differences Between RET Fusion-positive and BRAFV600E in Papillary Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae803
BibTeX
@article{Chen2025,
author = {Chen, Zixian and Sun, Wenyu and Fei, Mengjia and Qian, Kai and Shi, Yuan and Guo, Kai and Wang, Zhuoying},
title = {Clinical and Sonographic Differences Between RET Fusion-positive and BRAFV600E in Papillary Thyroid Carcinoma},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae803}
}
EUVIMED